David E. Lazar Sells 194,628,820 Shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Stock

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) CEO David E. Lazar sold 194,628,820 shares of the company’s stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $0.03, for a total value of $5,838,864.60. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Cyclacel Pharmaceuticals Price Performance

NASDAQ:CYCC opened at $0.33 on Friday. Cyclacel Pharmaceuticals, Inc. has a one year low of $0.30 and a one year high of $4.00. The business has a fifty day moving average price of $0.36 and a 200-day moving average price of $0.64. The firm has a market capitalization of $2.08 million, a price-to-earnings ratio of -0.04 and a beta of 0.35.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals in a research report on Thursday. They set a “sell” rating for the company.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.